Moleculin Biotech, Inc. (LON:0K2H)
4.020
-0.330 (-7.59%)
At close: Feb 11, 2026
Moleculin Biotech Employees
Moleculin Biotech had 17 employees as of December 31, 2024. The number of employees decreased by 1 or -5.56% compared to the previous year.
Employees
17
Change (1Y)
-1
Growth (1Y)
-5.56%
Revenue / Employee
n/a
Profits / Employee
-2.25M GBP
Market Cap
9.53M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 17 | -1 | -5.56% | 17 | 0 |
| Dec 31, 2023 | 18 | -1 | -5.26% | 18 | 0 |
| Dec 31, 2022 | 19 | 2 | 11.76% | 15 | 4 |
| Dec 31, 2021 | 17 | 2 | 13.33% | 13 | 4 |
| Dec 31, 2020 | 15 | -1 | -6.25% | 10 | 5 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Asia Strategic Holdings | 2,530 |
| Caffyns | 455 |
| Nanoco Group | 38 |
| Genflow Biosciences | 5 |
| Cloudbreak Discovery | 5 |
| Mila Resources | 5 |
| Critical Mineral Resources | 4 |
Moleculin Biotech News
- 4 weeks ago - Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects - GlobeNewsWire
- 4 weeks ago - Moleculin Biotech (MBRX) Readies Annamycin for Major Milestones in 2026 - GuruFocus
- 4 weeks ago - Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs - GlobeNewsWire
- 2 months ago - Moleculin's WP1066 Shows Immune Activity, Favorable Safety In Pediatric Brain Cancer Trial - Nasdaq
- 2 months ago - Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors - GlobeNewsWire
- 2 months ago - Moleculin Biotech (MBRX) Target Price Adjusted by Roth Capital Analyst - GuruFocus
- 2 months ago - Moleculin Biotech (MBRX) Sees Significant Price Target Upgrade - GuruFocus
- 2 months ago - Moleculin announces exercise of warrants for $6.8M - Seeking Alpha